Company Encyclopedia
View More
name
HYBIO
300199.SZ
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates.
3.159 T
300199.SZMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking94/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-9.95%D
    • Profit Margin-7.52%D
    • Gross Margin51.64%B
  • Growth ScoreA
    • Revenue YoY121.72%A
    • Net Profit YoY81.67%A
    • Total Assets YoY1.72%C
    • Net Assets YoY-8.81%D
  • Cash ScoreC
    • Cash Flow Margin-1330.57%E
    • OCF YoY121.72%A
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreE
    • Gearing Ratio78.99%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 968 million in funding

    Hybio Pharmaceutical Co., Ltd. announced a private placement of shares expected to raise up to CNY 968 million. The issuance will not exceed 30% of total share capital, with a minimum issue price of 80% of the average price over the previous 20 trading days. The transaction, approved by the company's 6th Directorate, requires further approvals from shareholders, the Shenzhen Stock Exchange, and the China Securities Regulatory Commission. Shares will be non-transferable for 6 months post-issuance.

    marketscreener·
    SZ
    300199
    +3.00%
    marketscreener·
    SZ
    300199
    +3.00%

    HYBIO plans to raise no more than 968 million yuan through a private placement for multiple projects and to supplement working capital

    HYBIO plans to issue A-shares to no more than 35 specific investors, raising no more than 968 million yuan. The issuance price will be 80% of the average price of the 20 trading days prior to the pricing benchmark date. The raised funds will be used for the expansion and construction of peptide drug production lines, green intelligent upgrades, research laboratory upgrades, and to supplement working capital

    Zhitong·
    SZ
    300199
    +3.00%
    Zhitong·
    SZ
    300199
    +3.00%

    Hybio Pharmaceutical Plans To Raise Fund Via Share Private Placement

    Hybio Pharmaceutical Co Ltd :SAYS CO PLANS TO RAISE UP TO 968 MILLION YUAN ($135.90 million) VIA SHARE PRIVATE PLACEMENT TO FUND PROJECTS, REPLENISH CAPITAL($1 = 7.1231 Chinese yuan renminbi)

    Reuters·
    SZ
    300199
    +3.00%
    Reuters·
    SZ
    300199
    +3.00%

    HYBIO: Plans to issue A-share stocks

    HYBIO announced that the company held a board of directors and supervisory board meeting on September 25, 2025, to review and approve the proposal for the issuance of A-shares to specific targets for the year 2025. The relevant preliminary plan and announcement have been disclosed on the Giant Tide Information Network. The related matters of this stock issuance still require approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission

    Zhitong·
    SZ
    300199
    +3.00%
    Zhitong·
    SZ
    300199
    +3.00%

    FOCUS-Chinese companies turn to generics as shipments behind US weight-loss craze fade

    Chinese companies are shifting focus to producing generic versions of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound as U.S. shipments decline due to regulatory restrictions. Eight Chinese firms, including Jiangsu Sinopep and Hybio Pharmaceutical, previously supplied raw ingredients for over a billion doses sold online. With patents expiring, these companies aim to launch their own generics, although manufacturing complexities may hinder explosive growth. The market for compounded drugs has diminished, leading to a significant drop in shipments of semaglutide and tirzepatide ingredients.

    Reuters·
    US
    LLY
    -0.41%
    US
    NVO
    -0.27%
    Reuters·
    US
    LLY
    -0.41%
    US
    NVO
    -0.27%
    © 2025 Longbridge｜Disclaimer